Comparison of the efficacy and safety of methotrexate injection and methotrexate tablets in active RA
Primary result · Change in DAS28-ESR, least squares meanResult — go to the resultIntergroup difference −0.173Authors' conclusion
SC MTX had similar overall therapeutic effects compared with OR MTX and was generally well tolerated.
Study context
- Population
- Chinese patients with active RA
- Comparison
- SC MTX vs OR MTX
- Primary endpoint
- DAS28-ESR
- Follow-up
- 12 weeks
Methodological detailsnon-inferiority
- Non-inferiority
Primary result
Change in DAS28-ESR, least squares mean · week 12
Intergroup difference
−0.173
Change by group
SC MTX
−1.972
least squares mean · SE 0.1448
OR MTX
−1.800
least squares mean · SE 0.1438
As reported in the abstract
Secondary outcomes
ACR20/50/70, DAS28-CRP and DAS28(CRP) remission · first 8 weeks and week 12
- SC MTX numerically better than OR MTX during the first 8 weeks but not all by week 12
Safety
Overall safety profile; drug-related GI TEAE
- Safety profile of SC MTX similar to OR MTX in general; incidence, occurrences and preferred term types of drug-related GI TEAE lower with SC MTX
Original publication
Comparison of the efficacy and safety of methotrexate injection and methotrexate tablets in active RA. Rheumatology (Oxford). Published 7 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →